C4 Therapeutics (CCCC) Total Current Liabilities (2019 - 2026)

C4 Therapeutics has reported Total Current Liabilities for 8 years, with the latest figure at $27.2 million in Q1 2026.

• For the quarter ending Q1 2026, Total Current Liabilities fell 33.25% year-over-year to $27.2 million; the trailing twelve-month figure through Mar 2026 stood at $27.2 million (down 33.25% YoY), and the FY2025 full-year result was $33.0 million, down 26.88% from the prior year.
• Total Current Liabilities for Q1 2026 stood at $27.2 million, down from $33.0 million in the prior quarter.
• The five-year high for Total Current Liabilities was $55.0 million in Q1 2024, with the low at $27.2 million in Q1 2026.
• Average Total Current Liabilities over 5 years is $42.5 million, with a median of $44.5 million recorded in 2025.
• Year-over-year, Total Current Liabilities jumped 43.02% in 2024 and slumped 33.25% in 2026.
• Tracing CCCC's Total Current Liabilities over 5 years: stood at $44.5 million in 2022, then retreated by 4.0% to $42.8 million in 2023, then rose by 5.64% to $45.2 million in 2024, then decreased by 26.88% to $33.0 million in 2025, then declined by 17.51% to $27.2 million in 2026.
• The last three Total Current Liabilities figures came in at $27.2 million (Q1 2026), $33.0 million (Q4 2025), and $35.9 million (Q3 2025), per Business Quant data.

Peer Comparison